A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

NCT04824924 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: The combination of HHT, venetoclax, AZA, G-CSF

Sponsor

Shanghai Jiao Tong University School of Medicine